

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

SECTION 1. IDENTIFICATION

Product name : Posaconazole Suspension Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical


SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Carcinogenicity (Inhalation) : Category 2

Reproductive toxicity : Category 2

Specific target organ systemic toxicity - repeated exposure (Oral) : Category 1 (Adrenal gland, Bone marrow, Kidney, Nervous system, Reproductive organs)

GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H351 Suspected of causing cancer if inhaled.
H361 Suspected of damaging fertility or the unborn child.
H372 Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.

Posaconazole Suspension Formulation

Version 2.2 Revision Date: 02/04/2016 SDS Number: 28777-00003 Date of last issue: 06/10/2015
Date of first issue: 11/06/2014

P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Glycerine	56-81-5	>= 10 - < 20
Posaconazole	171228-49-2	>= 1 - < 5
Titanium dioxide	13463-67-7	>= 0.1 - < 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms : Suspected of causing cancer if inhaled.

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

and effects, both acute and delayed	Suspected of damaging fertility or the unborn child. Causes damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be

Posaconazole Suspension Formulation

Version 2.2	Revision Date: 02/04/2016	SDS Number: 28777-00003	Date of last issue: 06/10/2015 Date of first issue: 11/06/2014
----------------	------------------------------	----------------------------	---

pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | |
|-----------------------------|--|
| Technical measures | : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : Use only with adequate ventilation. |
| Advice on safe handling | : Avoid inhalation of vapor or mist.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations. |
| Materials to avoid | : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	TWA (mist, respirable fraction)	5 mg/m ³	OSHA Z-1
		TWA (mist, total dust)	15 mg/m ³	OSHA Z-1
Posaconazole	171228-49-2	TWA	1,000 µg/m ³	Merck
Titanium dioxide	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA	10 mg/m ³	ACGIH

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
2.2	02/04/2016	28777-00003	06/10/2015
			Date of first issue: 11/06/2014

II			(Titanium dioxide)	
----	--	--	--------------------	--

Engineering measures : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material

: Impervious gloves

Remarks

: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection

: Wear the following personal protective equipment:
Safety glasses

Skin and body protection

: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

II **Hygiene measures**

: Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

Posaconazole Suspension Formulation

Version 2.2	Revision Date: 02/04/2016	SDS Number: 28777-00003	Date of last issue: 06/10/2015 Date of first issue: 11/06/2014
----------------	------------------------------	----------------------------	---

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: suspension
Color	: white
Odor	: No information available.
Odor Threshold	: No data available
pH	: 4.2 - 4.8
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Upper explosion limit	: No data available
Lower explosion limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Density	: 1 g/cm3
Solubility(ies) Water solubility	: soluble
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity Viscosity, dynamic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available

SECTION 10. STABILITY AND REACTIVITY

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Ingredients:**Glycerine:**

|| Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Posaconazole:

|| Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 3,000 mg/kg

|| Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Titanium dioxide:

|| Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

|| Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

|| Not classified based on available information.

Ingredients:**Glycerine:**

|| Result: No skin irritation

Posaconazole:

|| Species: Rabbit
Result: No skin irritation

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

||**Titanium dioxide:****||**

Species: Rabbit

||

Result: No skin irritation

Serious eye damage/eye irritation**||**

Not classified based on available information.

Ingredients:**Glycerine:****||**

Result: No eye irritation

||**Posaconazole:****||**

Species: Rabbit

||

Result: Mild eye irritation

Titanium dioxide:**||**

Species: Rabbit

||

Result: No eye irritation

Respiratory or skin sensitization**||**

Skin sensitization: Not classified based on available information.

||

Respiratory sensitization: Not classified based on available information.

Ingredients:**Posaconazole:****||**

Test Type: Magnusson-Kligman-Test

||

Routes of exposure: Skin contact

||

Species: Guinea pig

||

Result: negative

Titanium dioxide:**||**

Test Type: Local lymph node assay (LLNA)

||

Routes of exposure: Skin contact

||

Species: Mouse

||

Result: negative

Germ cell mutagenicity**||**

Not classified based on available information.

Ingredients:**Glycerine:****||**

Genotoxicity in vitro

||

: Test Type: In vitro mammalian cell gene mutation test

||

Method: OECD Test Guideline 476

||

Result: negative

Titanium dioxide:**||**

Genotoxicity in vitro

||

: Test Type: Bacterial reverse mutation assay (AMES)

||

Result: negative

||

Genotoxicity in vivo

||

: Test Type: In vivo micronucleus test

||

Species: Mouse

||

Result: negative

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

II**Carcinogenicity****II** Suspected of causing cancer if inhaled.**Ingredients:****Glycerine:**

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Posaconazole:

Species: Rat
Application Route: oral (feed)
Exposure time: 2 Years
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: negative

Titanium dioxide:

Species: Rat
Application Route: inhalation (dust/mist/fume)
Exposure time: 2 Years
Method: OECD Test Guideline 453
Result: positive
Remarks: The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

IARC Group 2B: Possibly carcinogenic to humans

Titanium dioxide 13463-67-7

OSHA No ingredient of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity**II** Suspected of damaging fertility or the unborn child.**Ingredients:****Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male
General Toxicity Parent: NOAEL (No observed adverse effect level): 180 mg/kg body weight
Symptoms: No effects on mating performance.
Result: negative

Test Type: Fertility/early embryonic development
Species: Rat, female
General Toxicity Parent: NOAEL (No observed adverse effect level): 45 mg/kg body weight
Symptoms: No effects on mating performance.
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat, female
Application Route: Oral
Frequency of Treatment: 6 - 15 days
Developmental Toxicity: LOAEL (Lowest observed adverse effect level): 29 mg/kg body weight
Result: Fetotoxicity., Malformations were observed.

Test Type: Embryo-fetal development
Species: Rabbit, female
Frequency of Treatment: 7 - 19 days
Developmental Toxicity: LOAEL (Lowest observed adverse effect level): 40 mg/kg body weight
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Ingredients:**Posaconazole:**

Routes of exposure: Ingestion

Target Organs: Adrenal gland, Bone marrow, Kidney, Reproductive organs, Nervous system

Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Ingredients:**

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

Glycerine:

Species: Rat
NOAEL: 167 mg/m³
LOAEL: 660 mg/m³
Application Route: inhalation (dust/mist/fume)
Exposure time: 13 Weeks
Symptoms: Local irritation

Posaconazole:

Species: Rat, female
LOAEL: 5 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, ovaries

Species: Dog
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 392 Days
Target Organs: Lungs, Liver, brain, small intestine, Adrenal gland

Species: Monkey
LOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 1 Months
Target Organs: Bone marrow, Adrenal gland, lymph node, Blood

Species: Dog
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 56 Weeks
Target Organs: Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus, Testes

Species: Monkey
LOAEL: 180 mg/kg
Application Route: Oral
Exposure time: 12 Months
Target Organs: Blood, Gastrointestinal tract, spleen

Species: Monkey
LOAEL: 8 mg/kg
Application Route: Intravenous
Exposure time: 1 Months
Target Organs: Cardio-vascular system, Lungs, Adrenal gland, Blood

Titanium dioxide:

Species: Rat
NOAEL: 24,000 mg/kg
Application Route: Ingestion
Exposure time: 28 Days

Species: Rat
NOAEL: 10 mg/m³
Application Route: inhalation (dust/mist/fume)
Exposure time: 2 yr

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

||

Aspiration toxicity

|| Not classified based on available information.

Experience with human exposure

Ingredients:

Posaconazole:

|| Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Ingredients:

Glycerine:

|| Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h

|| Toxicity to bacteria : NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h

Posaconazole:

|| Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.276 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

|| Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

|| M-Factor (Acute aquatic toxicity) : 1

|| Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.244 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211
 Remarks: No toxicity at the limit of solubility.

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to bacteria : EC50 (Natural microorganism): > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h

Toxicity to algae : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
 Exposure time: 72 h

Toxicity to bacteria : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Method: OECD Test Guideline 209

Persistence and degradability

Ingredients:

Glycerine:

Biodegradability : Result: Readily biodegradable.
 Biodegradation: 94 %
 Exposure time: 1 d

Posaconazole:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 50 %
 Exposure time: 28 h
 Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d
 Method: OECD Test Guideline 111

Bioaccumulative potential

Ingredients:

Glycerine:

Partition coefficient: n-octanol/water : log Pow: -1.76

Posaconazole:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

	Bioconcentration factor (BCF): 20
	Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4.15

Mobility in soil**Ingredients:****Posaconazole:**

Distribution among environmental compartments	: log Koc: 5.52
---	-----------------

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	: Dispose of in accordance with local regulations.
---------------------	--

Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
------------------------	---

SECTION 14. TRANSPORT INFORMATION**International Regulation****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Posaconazole)
Class	: 9
Packing group	: III
Labels	: 9

IATA-DGR

UN/ID No.	: UN 3082
Proper shipping name	: Environmentally hazardous substance, liquid, n.o.s. (Posaconazole)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 964
Packing instruction (passenger aircraft)	: 964

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

IMDG-Code

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Posaconazole)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

UN/ID/NA number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Posaconazole)
Class	: 9
Packing group	: III
Labels	: CLASS 9
ERG Code	: 171
Marine pollutant	: yes (Posaconazole)
Remarks	: Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 311/312 Hazards : Chronic Health Hazard

SARA 302 : No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
2.2	02/04/2016	28777-00003	06/10/2015
			Date of first issue: 11/06/2014

US State Regulations

Pennsylvania Right To Know

Water	7732-18-5	30 - 50 %
Glucose	50-99-7	30 - 50 %
Glycerine	56-81-5	10 - 20 %
Posaconazole	171228-49-2	1 - 5 %

New Jersey Right To Know

Water	7732-18-5	30 - 50 %
Glucose	50-99-7	30 - 50 %
Glycerine	56-81-5	10 - 20 %
Posaconazole	171228-49-2	1 - 5 %
Polyethylene glycol sorbitan monooleate	9005-65-6	1 - 5 %

California Prop. 65

WARNING! This product contains a chemical known in the State of California to cause cancer.

Titanium dioxide	13463-67-7
------------------	------------


The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS III:

HEALTH	0*
FLAMMABILITY	1
PHYSICAL HAZARD	0

0 = not significant, 1 = Slight,
2 = Moderate, 3 = High
4 = Extreme, * = Chronic

Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	: 8-hour, time-weighted average
OSHA Z-1 / TWA	: 8-hour time weighted average

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 02/04/2016

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

Posaconazole Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/10/2015
2.2	02/04/2016	28777-00003	Date of first issue: 11/06/2014

US / Z8